Connect Biopharma Holdings Limited

No trades
See on Supercharts
Market capitalization
50.666MUSD
−1.5856USD
−118.368MUSD
Beta
0.46

About Connect Biopharma Holdings Limited

CEO
Zheng Wei
Headquarters
Taicang
Employees (FY)
100
Founded
2015
ISIN
US2075231017
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Performance
Revenue to profit conversion
Earnings
Next:
‪0‬
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Interactive Brokers
Stocks, Futures, Bonds
4.4Very Good

See all brokers